5 Best Peptides for Frozen Shoulder

What to Know Before Choosing a Peptide for Frozen Shoulder

Frozen shoulder, clinically called adhesive capsulitis, is a fibrotic condition. The joint capsule becomes inflamed, fibroblasts transform into scar-producing cells, and excessive collagen accumulates until the shoulder locks into a painful, restricted range of motion. Standard recovery takes twelve to eighteen months on average. That long, grinding timeline is exactly why people go looking for something to accelerate it.

Every compound in this guide earned its place because people use it or are actively discussing using it for frozen shoulder recovery. That is the only test a compound has to pass to appear here. FDA approval is not the test, randomized trial data is not the test, and commercial availability is not the test. A compound that exists only in a research setting or that moves exclusively through community protocols is every bit as eligible as one with a published clinical trial. What varies across these entries is the quality of evidence behind each, and that evidence is described honestly in the entry for that compound rather than used as a reason to quietly leave it off the list.

The order reflects how prominently each compound shows up in research and real-world use for frozen shoulder. The first entry does not mean "the best choice for you," and the last entry does not mean "least worth knowing about." These are different tools with different evidence bases, different mechanisms, and different accessibility profiles. Getting from this map to a specific, personalized plan is what MyPeptidePal is built to do.

1. BPC-157: The Most Widely Used Option for Shoulder Recovery

BPC-157 stands for Body Protection Compound-157. It is a synthetic pentadecapeptide, fifteen amino acids long, derived from a protein found in gastric juice. It is not FDA-approved for any musculoskeletal condition, and it has been on the World Anti-Doping Agency's banned list since 2022, so athletes competing in WADA-governed sports should be aware. In the United States it is accessible through compounding pharmacies under physician supervision on an off-label basis. It also circulates through unregulated research-chemical channels where quality and purity cannot be verified, and the risks of those sources are meaningfully different from what a licensed compounding pharmacy provides.

For frozen shoulder specifically, BPC-157 is the compound most people in the peptide community reach for first. Its general tissue repair properties are the draw: it promotes angiogenesis (the growth of new blood vessels that deliver oxygen and repair materials to damaged tissue), supports tendon and ligament healing, and appears to modulate inflammation. Those mechanisms do not target capsular fibrosis as precisely as relaxin-2 does, but they address the inflammation and connective tissue damage that sit underneath the condition and drive its most painful stages.

No published human clinical trial exists for BPC-157 in frozen shoulder as of 2026. The closest human data is a small retrospective study of twelve people using it for knee pain, which is a different context entirely. What exists for frozen shoulder is a substantial and consistent body of user-reported experience. Across dedicated frozen shoulder forums and biohacking communities, people using BPC-157 report meaningful reductions in pain and recovery timelines that feel considerably faster than the standard course. One account describes going from two years of frozen shoulder to roughly ninety percent improvement over eight weeks. Another describes regaining the ability to lift the affected arm to shoulder height the morning after a first injection. These accounts are striking, but they are user-reported from an uncontrolled setting, and individual results vary widely.

BPC-157 is most commonly used alongside TB-500. Users who report outcomes for BPC-157 alone, rather than the combined stack, are less common in community literature, which makes it difficult to separate what each compound contributes independently.

2. TB-500: Anti-Inflammatory Repair Partner and the Wolverine Stack

TB-500 is a synthetic analog of thymosin beta-4, a protein the body produces naturally and uses to regulate cell migration, tissue repair, and inflammation. Like BPC-157, it is not FDA-approved for any musculoskeletal indication and is accessible through compounding pharmacies on an off-label basis under physician supervision. It also moves through unregulated research-chemical channels carrying the same quality and contamination concerns.

TB-500's mechanism is distinct from BPC-157's in a way that makes the combination appealing. Where BPC-157 is described primarily as a tissue-repair and angiogenesis compound, TB-500 is valued for its anti-inflammatory action and its support for organized collagen deposition, meaning new tissue that forms with better structural quality rather than as random, rigid adhesions. In the frozen shoulder context, reducing systemic inflammation and guiding the quality of new tissue are both relevant. The freezing and early frozen stages are heavily inflammatory, and the scar tissue that accumulates during fibrosis has a disorganized collagen architecture that contributes to the restricted motion.

The Wolverine Stack is the name community users have given to the BPC-157 and TB-500 combination. It is the most discussed peptide approach for frozen shoulder by a significant margin, and the most dramatic recovery accounts in user forums almost always reference both compounds together. One person running the stack reports regaining arm mobility to shoulder height the morning after a first injection, ceiling reach by the second morning, and gradual full restoration over three months. Another reports going from two years of frozen shoulder to ninety percent improvement in eight weeks, used alongside anti-inflammatory supplements. A third describes improvement over approximately six months, comparable in duration to standard recovery but considerably less painful throughout. All of these are user-reported outcomes from uncontrolled settings, not clinical data, and they should be read as community experience rather than predicted outcomes.

No published human clinical trial exists for TB-500 in frozen shoulder as of 2026. Animal models support its general tissue repair and anti-inflammatory properties, but the translation to human frozen shoulder has not been formally studied. Community sources consistently recommend pairing any peptide protocol for frozen shoulder with physical therapy, and this advice appears well-founded: the capsule needs to be mobilized mechanically even as inflammation and fibrosis are addressed at a cellular level.

3. Relaxin-2: The Most Mechanistically Targeted Compound

Relaxin-2 is a naturally occurring peptide hormone in the insulin superfamily, and it holds a unique position in this list. It is the only compound here with a directly demonstrated mechanism for reversing the specific fibrotic pathology that defines frozen shoulder. It is also the only compound here that is completely inaccessible outside a research or clinical trial setting. Both of those things are worth understanding before reading further.

The mechanism is precise in a way that matters for frozen shoulder. Relaxin-2 binds to a receptor called RXFP1, a G-protein coupled receptor found on fibroblasts. That binding triggers an intracellular cascade that increases cAMP, downregulates TGF-beta-1 (the primary signaling molecule that drives the transformation of normal fibroblasts into the scar-producing cells responsible for capsular thickening), suppresses type I collagen production, and upregulates two enzymes called MMP-1 and MMP-3. Those enzymes actively degrade the dense collagen mesh that forms the adhesions. In plain terms: relaxin-2 targets the molecular switch that converts normal fibroblasts into the cells building the frozen shoulder capsule, and it activates the enzymes that break down the scar tissue once it is already there. No other peptide in this guide acts on those specific points in the fibrotic pathway.

A 2019 study published in the Proceedings of the National Academy of Sciences tested multiple intraarticular injections of relaxin-2 in a mouse model of shoulder arthrofibrosis. The results showed restored range of motion and eliminated capsular fibrosis, with no adverse events in the animal model. The study has been cited sixty-six times in the peer-reviewed literature, and the authors described the findings as encouraging for further clinical development.

What has not happened since is a human trial. No Phase III study of relaxin-2 in frozen shoulder has been published or is currently recruiting. An important cautionary note for anyone tracking this compound: a Phase III trial of relaxin-2 for heart failure administered intravenously was halted due to limited efficacy in humans, which illustrates that promising animal results do not automatically translate across species or delivery routes. Relaxin-2 for frozen shoulder remains animal data only. It is not commercially available. It appears on this list because the mechanism is the most directly relevant of any compound discussed here, and because practitioners and researchers discussing frozen shoulder at a biological level consistently return to it as the compound that would theoretically fit best if a human trial were to be run and succeed.

4. GHK-Cu: Tissue Remodeling Support During Later-Stage Recovery

GHK-Cu is a copper-binding tripeptide that occurs naturally in human plasma. It has been studied for its effects on wound healing, collagen synthesis, and anti-inflammatory signaling across a range of contexts, and it is accessible through compounding pharmacies, making it one of the more practically available options on this list.

For frozen shoulder, GHK-Cu is not being discussed as a primary treatment for the fibrosis itself. Its proposed role, as it appears in practitioner discussion and in the less common user accounts that mention it, is as a supporting compound during the remodeling phase. That is the later stage of recovery when acute inflammation has subsided and the body is rebuilding and reorganizing the damaged tissue. GHK-Cu is thought to regulate a large number of genes involved in tissue repair and inflammation resolution, and the structural quality of tissue forming during remodeling may be influenced by whether those regulatory signals are functioning well.

The evidence for GHK-Cu in frozen shoulder specifically is theoretical. No clinical trial and no published human data exist for this use as of 2026. Its presence in the conversation is grounded in its general tissue-repair and anti-inflammatory properties rather than any frozen shoulder-specific mechanism or outcome data. In practice it shows up as a supporting layer in broader protocols rather than an anchor compound, typically used alongside something like BPC-157 in the later stages of recovery rather than as a standalone approach.

5. Sermorelin and CJC-1295: Systemic Recovery Support in Broader Protocols

Sermorelin and CJC-1295 are growth hormone-releasing hormone analogs. They signal the pituitary gland to release more of the body's own growth hormone rather than supplying synthetic GH directly, a distinction that matters for the body's natural feedback rhythms. Both are among the more widely prescribed peptides in functional medicine and telehealth settings, used for general recovery, tissue repair, and metabolic support. Both are accessible through compounding pharmacies under physician supervision.

In the frozen shoulder context, neither compound targets the fibrotic mechanism specifically. They do not act on TGF-beta-1, do not modulate the collagen adhesion pathway, and are not being discussed in community forums as primary treatments for the condition. Where they appear is in broader recovery protocols, particularly among people using a range of supportive compounds alongside a primary peptide and physical therapy. The logic is systemic: growth hormone supports muscle and tissue repair generally, and maintaining a favorable repair environment across a long recovery from frozen shoulder has at least a theoretical basis.

The evidence for sermorelin or CJC-1295 in frozen shoulder specifically does not exist as of 2026. No published data covers these compounds in this context. Their presence on this list reflects the fact that practitioners sometimes include them in broader musculoskeletal recovery protocols, and that some people using peptides for frozen shoulder add them alongside other compounds. Anyone considering them should understand they are the most general-purpose entries here, with the least frozen-shoulder-specific rationale of any compound in this guide.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for frozen shoulder?

No peptide on this list is FDA-approved for treating frozen shoulder or adhesive capsulitis. BPC-157, TB-500, GHK-Cu, sermorelin, and CJC-1295 are all used off-label through compounding pharmacies under physician supervision. Relaxin-2 is not commercially available in any form. Off-label use under qualified medical supervision is legal, but it does not carry the safety and efficacy guarantees that an approved indication provides.

What is the Wolverine Stack and why do people use it for frozen shoulder?

The Wolverine Stack is the community name for BPC-157 and TB-500 used together. The two compounds are thought to complement each other: BPC-157 supports tendon and ligament repair and promotes new blood vessel growth to the damaged area, while TB-500 addresses inflammation and supports the quality of new tissue formation. Most of the striking recovery accounts in frozen shoulder communities reference this combination rather than either peptide alone, though the evidence behind it is entirely user-reported and no controlled trial exists for the combination in frozen shoulder.

How long do people typically report before noticing improvement?

User-reported timelines vary considerably and should not be read as clinical predictions. Some accounts describe initial mobility improvements within the first few days; others describe gradual improvement over six months or more, roughly comparable to standard recovery timelines but with less pain throughout. No controlled data exists to establish what a typical timeline looks like, and individual variation in frozen shoulder itself is substantial regardless of what treatment approach someone uses.

Is there a peptide with genuine human trial data for frozen shoulder?

Not among the synthetic peptides most commonly discussed for this condition. Calcitonin, a naturally occurring peptide hormone delivered as an intranasal spray, has published human trial data showing faster pain and function improvement compared to placebo in frozen shoulder patients. Its role is symptom management rather than addressing the underlying fibrosis, and it sits in standard medical practice rather than the peptide community discussion this guide covers. Among the compounds people typically mean when they search for peptides for frozen shoulder, no published human trial data exists as of 2026.

What safety concerns should someone know before pursuing any of these peptides?

The primary concern is the absence of long-term human safety data for any of these compounds in musculoskeletal use. Reported side effects include injection site reactions, headaches, fatigue, and potential metabolic changes. Compounds sourced through unregulated research-chemical channels carry additional contamination and quality risks that licensed compounding pharmacies do not. People with a history of cancer should discuss the growth-promoting properties of repair-focused peptides with their physician before considering them. Anyone pursuing off-label peptide use for frozen shoulder should do so under the supervision of a physician experienced with these compounds and should source only through licensed compounding pharmacies.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for frozen shoulder in one place.